<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="135">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369820</url>
  </required_header>
  <id_info>
    <org_study_id>2020-14</org_study_id>
    <secondary_id>IDRCB</secondary_id>
    <nct_id>NCT04369820</nct_id>
  </id_info>
  <brief_title>C5a Receptor Expression - COVID-19 (C5-COV)</brief_title>
  <acronym>C5-COV</acronym>
  <official_title>C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pathophysiology of ARDS is linked to an uncontrolled inflammatory response at the level
      of alveolo-capillary membrane, mediated by neutrophils and mononuclear cells. The complement
      system and anaphylatoxin C5a have shown central role in the recruitment of these
      pro-inflammatory cells and more broadly in the genesis of cytokinic storm syndrome. C5a acts
      via receptors C5aR and C5L2.

      This is a preliminary study aimed at studying the expression of the C5a receptor on myeloid
      cells in peripheral blood of patients with ARDS secondary to COVID-19.

      This study has of primary objective to show there is an overexpression of the C5a receptor in
      patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19
      without respiratory distress and healthy volunteers).

      The medium-term objective is to develop a clinical trial to test the effectiveness of
      anti-C5aR antibody in this condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiology of ARDS is linked to an uncontrolled inflammatory response at the level
      of alveolo-capillary membrane, mediated by neutrophils and mononuclear cells. The complement
      system and anaphylatoxin C5a have shown central role in the recruitment of these
      pro-inflammatory cells and more broadly in the genesis of cytokinic storm syndrome. C5a acts
      via receptors C5aR and C5L2.

      This is a preliminary study aimed at studying the expression of the C5a receptor on myeloid
      cells in peripheral blood of patients with ARDS secondary to COVID-19.

      This study has of primary objective to show there is an overexpression of the C5a receptor in
      patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19
      without respiratory distress and healthy volunteers).

      The medium-term objective is to develop a clinical trial to test the effectiveness of
      anti-C5aR antibody in this condition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).</measure>
    <time_frame>72 hours</time_frame>
    <description>The endpoint is the expression of the C5a receptor (C5aR) in peripheral blood myeloid cells, expressed as a percentage of cells expressing C5a receptor and as median fluorescence intensity (MFI), during the first 72 hours of patient management in resuscitation unit.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>COVID-19 PATIENTS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two blood samples (40mL) at 2 different points in time:
Within the first 72 hours of medical care in resuscitation unit or department.
Between the 5th and the 10th day of medical care (ideally at the end of the first week) or on the day of discharge of patient if it is earlier, or of death if it takes place earlier.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>draw blood</intervention_name>
    <description>40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.</description>
    <arm_group_label>COVID-19 PATIENTS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For patients in resuscitation unit with ARDS linked to COVID-19:

          -  Patient under invasive mechanical ventilation

          -  PaO2 / FiO2 &lt;300

          -  PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample

        For control patients with COVID-19 without ARDS

          -  Oxygen flow always less than 5 L / min

          -  PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample

          -  No passage in resuscitation unit

          -  Favorable evolution

        Exclusion Criteria:

          -  Minors

          -  Patient deprived of liberty

          -  Patient's refusal to participate at study

          -  Patient for whom therapeutic limitation measures such as non-admission to intensive
             care have been issued

          -  Medullar aplasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie EGP GARRIDO-PRADALIE</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien JC CARVELLI, MD</last_name>
    <phone>04 13 42 95 35</phone>
    <phone_ext>+33</phone_ext>
    <email>Julien.CARVELLI@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kahéna KA AMICHI</last_name>
    <phone>04 91 38 19 66</phone>
    <phone_ext>+33</phone_ext>
    <email>Kahena.AMICHI@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien CARVELLI</last_name>
      <phone>04 13 42 95 35</phone>
      <phone_ext>+33</phone_ext>
      <email>Julien.CARVELLI@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Kahéna AMICHI</last_name>
      <phone>04 91 38 19 66</phone>
      <phone_ext>+33</phone_ext>
      <email>kahena.amichi@ap-hm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marc GAINNIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas SCHLEINITZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel VELLY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent PAPAZIAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Yves CORDIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Kinross P, Suetens C, Gomes Dias J, Alexakis L, Wijermans A, Colzani E, Monnet DL; ECDC Public Health Emergency Team. Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union/European Economic Area and the United Kingdom, 1 January to 15 March 2020. Euro Surveill. 2020 Mar;25(11). doi: 10.2807/1560-7917.ES.2020.25.11.2000285. Epub 2020 Mar 16.</citation>
    <PMID>32186277</PMID>
  </reference>
  <reference>
    <citation>Parmet WE, Sinha MS. Covid-19 - The Law and Limits of Quarantine. N Engl J Med. 2020 Apr 9;382(15):e28. doi: 10.1056/NEJMp2004211. Epub 2020 Mar 18.</citation>
    <PMID>32187460</PMID>
  </reference>
  <reference>
    <citation>Gostin LO, Hodge JG Jr, Wiley LF. Presidential Powers and Response to COVID-19. JAMA. 2020 Apr 28;323(16):1547-1548. doi: 10.1001/jama.2020.4335.</citation>
    <PMID>32186661</PMID>
  </reference>
  <reference>
    <citation>Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA. 2020 Apr 28;323(16):1545-1546. doi: 10.1001/jama.2020.4031.</citation>
    <PMID>32167538</PMID>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.</citation>
    <PMID>32109013</PMID>
  </reference>
  <reference>
    <citation>Herrero R, Sanchez G, Lorente JA. New insights into the mechanisms of pulmonary edema in acute lung injury. Ann Transl Med. 2018 Jan;6(2):32. doi: 10.21037/atm.2017.12.18. Review.</citation>
    <PMID>29430449</PMID>
  </reference>
  <reference>
    <citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.</citation>
    <PMID>32187464</PMID>
  </reference>
  <reference>
    <citation>Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, Whitmore A, Heise MT, Baric RS. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio. 2018 Oct 9;9(5). pii: e01753-18. doi: 10.1128/mBio.01753-18.</citation>
    <PMID>30301856</PMID>
  </reference>
  <reference>
    <citation>Wang R, Xiao H, Guo R, Li Y, Shen B. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015 May;4(5):e28. doi: 10.1038/emi.2015.28. Epub 2015 May 6. Review.</citation>
    <PMID>26060601</PMID>
  </reference>
  <reference>
    <citation>Jiang Y, Zhao G, Song N, Li P, Chen Y, Guo Y, Li J, Du L, Jiang S, Guo R, Sun S, Zhou Y. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24;7(1):77. doi: 10.1038/s41426-018-0063-8.</citation>
    <PMID>29691378</PMID>
  </reference>
  <reference>
    <citation>Stevens JH, O'Hanley P, Shapiro JM, Mihm FG, Satoh PS, Collins JA, Raffin TA. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest. 1986 Jun;77(6):1812-6.</citation>
    <PMID>3711336</PMID>
  </reference>
  <reference>
    <citation>Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, Schmal H, Friedl HP, Ward PA. Protective effects of C5a blockade in sepsis. Nat Med. 1999 Jul;5(7):788-92.</citation>
    <PMID>10395324</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>ARDS</keyword>
  <keyword>C5a receptors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

